The antagonism in vitro with the combination of amphotericin B imidazole suggests that caution must be exercised before prescribing the antifungal drugs in combination for man. The frequent synergy of flucytosine with econazole is, however, encouraging because of the low toxicity of the 2 drugs. Under the limited conditions described, the combination of flucytosine and amphotericin B was not found synergistic but additive on the strains of C. albicans used in this study. This combination was found synergistic for a strain of C. parapsilosis and is useful for avoiding resistance to flucytosine.
Introduction
The usual doses of antifungal agents used in human therapy are fungistatic and not fungicidal.
Numerous fungi have a high mutation rate in the presence of flucytosine when this drug is given alone. The chromosomal mutation involves development of secondary resistant strains which do not respond to flucytosine. By using 2 antifungal agents, failures in therapy are less likely to occur. Better results are produced and the emergence of mutants resistant to one of the drugs is suppressed. However, an association of 2 antifungal agents is not always synergistic and the result of their action is sometimes only additive or even antagonistic. It is consequently necessary to test in vitro the effect of the association of 2 antifungal agents on the strain responsible for the mycosis (Ansehn, 1977; Dupont and Drouhet, 1978; Medoff, Comfort and Kobayashi, 1971; Polak, 1974; Shadomy, Wagner and Davis, 1975 (Dupont and Drouhet, 1978) . This method is derived from a technique using paper strips impregnated with antibiotics employed in bacteriology for the study of antibacterial combinations (Chabbert, 1973) .
Materials and methods
Twenty-six strains of Candida albicans, 22 strains of Cryptococcus neoformans all of human origin and one strain of Candida parapsilosis, agent of a fungal endocarditis (Dupont, Drouhet and Lapresle, 1977) were studied. The inoculum for the tests contained 106 yeast cells/ml cultured by shaking for 18 hr in Sabouraud glucose liquid medium.
The media used were: yeast morphology agar (YMA, Difco), a chemically defined medium which permits the testing of flucytosine, amphotericin B and imidazole derivatives, and a complex medium consisting of casitone Difco 19 g, yeast extract 5 g, sodium nitrate 10 g, disodium phosphate one g, charcoal purified glucose 10 g, agar 20 g, water 1000 ml.
This medium (pH 6.6) is effective for testing amphotericin B and econazole but not for flucytosine.
The media were poured into Petri dishes (15 ml for a 9-cm diameter dish) and dried for 30 min in the incubator. Four channels (40 mm long, 2 mm wide) were cut in the agar. The channels were at right angles to each other but not connected. The concentrations of the antifungal agents in the channels were as follows: 10 mg/l for amphotericin B (Table 3) . Synergism between flucytosine and econazole was observed with 2 flucytosine-resistant strains.
The combination of flucytosine and amphotericin B shows only an additive or indifferent effect. However, it was possible to show synergy with this combination against a strain of C. parapsilosis. The strain was obtained from a woman with endocarditis following a Starr-Edwards prosthesis . Treatment with this combination of antifungal drugs was successful and further surgery was unnecessary.
With Cr. neoformans, the results are similar to those for C. albicans and, for all the 22 strains tested, the authors have not observed synergism between amphotericin B and flucytosine. However, antagonism is constantly observed between amphotericin B and econazole or miconazole (Table 3) .
The combination of flucytosine and econazole is less often and less intensively synergistic for Cryptococcus than for Candida.
A strong synergistic effect was observed for 6 of 22 strains; nevertheless, 17 of the 22 were resistant to flucytosine and synergism was not observed in these 17 strains.
Discussion
The Candida and Cryptococcus genera show a similar antagonism to the combination of amphotericin B and imidazole. The in vitro results are dependent on various conditions: medium, inoculum and antifungal concentration. Such results do not necessarily permit a direct extrapolation to in vivo conditions. However, Schacter, Owellen and Buck (1976) found this antagonism in man. For Ansehn (1977) , an in vitro study suggested a synergy of the amphotericin B econazole association for C. albicans. The authors' preliminary studies on Torulopsis sp. demonstrate an antagonism of this genus to the combination of amphotericin B and imidazole, so that it is possible that this may also apply to all 3 genera.
The combination of flucytosine and imidazole is often synergistic, particularly against C. albicans. The synergy may even exist with strains resistant to flucytosine as already shown for the combination of flucytosine and amphotericin B. In contrast to other workers, the authors were not able to find a synergy between flucytosine and amphotericin B for C. albicans. This might be due to the synthetic medium as well as to the differences mentioned above (material and methods). Nevertheless, this combination is very useful in practice as amphotericin B suppresses the resistant mutants.
